|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM) and autologous stem-cell transplantation in patients with non-Hodgkin's lymphoma who were considered ineligible for total-body irradiation because of older age or prior radiotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:FalkPeterP,
pubmed-author:FormanStephen JSJ,
pubmed-author:FungHenry CHC,
pubmed-author:KrishnanAmritaA,
pubmed-author:MolinaArturoA,
pubmed-author:NademaneeAuaypornA,
pubmed-author:PalmerJoycelynne MJM,
pubmed-author:RaubitschekAndrew AAA,
pubmed-author:RodriguezRobertoR,
pubmed-author:SpielbergerRicardo TRT,
pubmed-author:YamauchiDaveD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
90-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18025438-Adult,
pubmed-meshheading:18025438-Aged,
pubmed-meshheading:18025438-Antibodies, Monoclonal,
pubmed-meshheading:18025438-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18025438-Carmustine,
pubmed-meshheading:18025438-Combined Modality Therapy,
pubmed-meshheading:18025438-Cytarabine,
pubmed-meshheading:18025438-Disease-Free Survival,
pubmed-meshheading:18025438-Female,
pubmed-meshheading:18025438-Humans,
pubmed-meshheading:18025438-Lymphoma, Follicular,
pubmed-meshheading:18025438-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:18025438-Lymphoma, Mantle-Cell,
pubmed-meshheading:18025438-Lymphoma, Non-Hodgkin,
pubmed-meshheading:18025438-Male,
pubmed-meshheading:18025438-Melphalan,
pubmed-meshheading:18025438-Middle Aged,
pubmed-meshheading:18025438-Neoplasm Recurrence, Local,
pubmed-meshheading:18025438-Podophyllotoxin,
pubmed-meshheading:18025438-Radioimmunotherapy,
pubmed-meshheading:18025438-Stem Cell Transplantation,
pubmed-meshheading:18025438-Treatment Outcome,
pubmed-meshheading:18025438-Yttrium Radioisotopes
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. akrishnan@coh.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
